Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1305
  • Dowloads 105

Original Research

Open Access

Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas

  • P. Petignat1,2,*,
  • M. Usel3
  • P. Gauthier1
  • Y. Popowski4
  • M.F. Pelte5
  • C. Bouchardy3
  • H.M. Verkooijen3

1Gynecologic Oncology Service, Centre hospitalier de l’Université de Montréal (CHUM) - Hôpital Notre-Dame, Montréal, Quebec, Canada

2Department of Obstetrics and Gynecology, Gynecologic Oncology and Senology Unit, Geneva University Hospitals,Switzerland

3Geneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University, Switzerland

4Department of Radiation Oncology, Geneva University Hospitals, Switzerland

5Department of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland

DOI: 10.12892/ejgo20080157 Vol.29,Issue 1,January 2008 pp.57-60

Published: 10 January 2008

*Corresponding Author(s): P. Petignat E-mail: patrick.petignat@hcuge.ch

PDF (73.1 kB) View Full-text

Abstract

Objectives: Our aim was to compare the survival between patients with clear cell carcinoma (CC) and patients with endometrioid carcinoma (EC). Methods: Through the population-based Geneva Cancer Registry, we identified 1,380 resident women diagnosed with uterine cancer between 1970 and 2000. We excluded those with papillary serous endometrial carcinoma and uterine sarcomas. We categorized patients as CC (n = 32, 2.8%) or EC (n = 1, 145, 97.2%). Uterine cancer-specific survival rates were calculated by Kaplan-Meier analysis. We used Cox proportional hazards analysis to compare uterine cancer mortality risks between groups, and adjusted these risks for other prognostic factors. Results: CC patients presented with a more advanced stage at diagnosis than EC patients (p = 0.002). Compared to women with EC, women with CC had a significantly greater risk of dying from their disease (hazard ratio [HR] 2.9, 95% confidence interval (95% CI) 1.7-4.9). After adjustment for age, stage and adjuvant chemotherapy, the risk of dying from uterine cancer was still significantly higher for CC patients (HR 2.0, 95% CI 1.2-3.4). By univariate analysis, the risk of dying of endometrial cancer was not significantly higher in CC patients than in patients with poorly-differentiated EC (HR 1.3, 95% CI 0.7-2.3). Conclusion: This population-based investigation shows that patients with CC have a poorer outcome than those with EC. Studies to determine the role of adjuvant treatment in CC patients are needed.

Keywords

Adjuvant chemotherapy; Endometrioid carcinoma; Clear cell carcinoma; Survival

Cite and Share

P. Petignat,M. Usel,P. Gauthier,Y. Popowski,M.F. Pelte,C. Bouchardy,H.M. Verkooijen. Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. European Journal of Gynaecological Oncology. 2008. 29(1);57-60.

URL:

https://www.ejgo.net/articles/10.12892/ejgo20080157

References

[1] Creasman W.T., Kohler M.F., Odicino F., Maisonneuve P., Boyle P.: “Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium”. Gynecol. Oncol., 2004, 95, 593.

[2] Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A. et al.: “Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers”. Br. J. Cancer, 2006, 13, 642.

[3] Cirisano F.D. Jr, Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S. et al.: “The outcome of Stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with EC”. Gynecol. Oncol., 2000, 77, 55.

[4] Webb G.A., Lagios M.D.: “Clear cell carcinoma of the endometrium”. Am. J. Obstet. Gynecol., 1987, 156, 1486.

[5] Carcangiu M.L., Chambers J.T.: “Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival”. Int. J. Gynecol. Pathol., 1995, 14, 30.

[6] Abeler V.M., Vergote I.B., Kjorstad K.E., Trope C.G.: “Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern”. Cancer, 1996, 78, 1740.

[7] Photopulos G.J., Carney C.N., Edelman D.A., Hughes R.R., Fowler W.C. Jr, Walton L.A.: “Clear cell carcinoma of the endometrium”. Cancer, 1979, 43, 1448.

[8] Malpica A., Tornos C., Burke T.W., Silva E.G. et al.: “Low-stage clear-cell carcinoma of the endometrium”. Am. J. Surg. Pathol., 1995, 19, 769.

[9] Murphy K.T., Rotmensch J., Yamada S.D., Mundt A.J.: “Outcome and patterns of failure in pathologic Stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy”. Int. J. Rad. Oncol. Biol. Phys., 2003, 55, 1272.

[10] Alektiar K.M., McKee A., Lin O., Venkatraman E., Zelefsky M.J., McKee B. et al.: “Is there a difference in outcome between Stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?”. Int. J. Rad. Oncol. Biol. Phys., 2002, 54, 79.

[11] Giri P.G., Schneider V., Belgrad R.: “Clear cell carcinoma of the endometrium: An uncommon entity with a favorable prognosis”. Int. J. Radiat. Oncol. Biol. Phys., 1981, 7, 1383.

[12] Bouchardy C.: “Cancer Incidence in Five Continents”. Vol VII. Lyon, France, International Agency for Research on Cancer, 1997, 666.

[13] WHO, ICD-O International Classification of Diseases for Oncology. 1976.

[14] Trope C., Kristensen G.B., Abeler V.M.: “Clear-cell and papillary serous cancer: treatment options”. Best. Pract. Res. Clin. Obstet. Gynaecol., 2001, 15, 433.

[15] Kurman R.J., Scully R.E.: “Clear cell carcinoma of the endometrium: an analysis of 21 cases”. Cancer, 1976, 37, 872.

Submission Turnaround Time

Top